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Low-molecular weight iron 
dextran and iron sucrose have 
similar comparative safety 
profiles in chronic kidney disease
M Auerbach1 and K Al Talib2
Serious adverse events that occur with the administration of iron 
dextran are due to the high molecular weight preparations.  Conclusions 
that iron sucrose and ferric gluconate are safer than iron dextran may be 
premature.  Published literature comparing safety profiles of available 
parenteral iron products is reviewed.  Administration of iron salts to 
pre-dialysis patients with chronic kidney disease may not be optimal.  
We recommend the total dose infusion of low molecular weight iron 
dextran as an option for iron replacement.
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Theoretical concerns about the long-
term toxicity of intravenous iron in 
renal disease have not been supported 
by recent observational studies of dialy-
sis patients.1,2 Publications also continue 
to raise concerns over anaphylaxis with 
iron dextran and infusion-related adverse 
events. Recent publications in Kidney 
International3,4 raise questions about the 
optimal method of administering intra-
venous iron. They propose an aggressive 
repletion regimen of iron sucrose given 
as a 500 mg infusion over 3 hours. Their 
recommendations are based on two 
premises: ﬁrst, that iron dextran is less 
safe than iron sucrose (Venofer; Ameri-
can Regent, USA, and Vifor, Switzerland) 
and, second, that the higher-than-rec-
ommended dosing of iron sucrose5 is 
justified by a considerably increased 
convenience to patient and physician. 
However, it is important to point out 
that the authors do not directly compare 
the safety of the two agents. Furthermore, 
there is no mention of the relevant dif-
ferences between the low-molecular 
weight iron dextran, INFeD (Watson, 
USA) and CosmoFer (Pharmacosmos, 
Denmark), and high-molecular weight 
preparations of iron dextran, Imferon 
(Fisons, UK) and Dexferrum (American 
Regent, USA, and Vifor, Switzerland). 
The published safety diﬀerences among 
these preparations will be discussed later 
in this Commentary.
One should not consider optimal a 
regimen of intravenous iron sucrose 
given as 500 mg over 3 hours for 2 con-
secutive days, as higher doses of intra-
venous iron are best given as a single 
total-dose infusion of low-molecular 
weight iron dextran.6 This method of 
intravenous iron administration is more 
convenient to physician and patient, is 
less expensive, allows the administra-
tion of doses up to 3,000 mg in a single 
setting, and is not more toxic. Both iron 
sucrose and ferric gluconate can be given 
as 5-minute infusions of 200–300 mg, but 
larger doses, even if given over a longer 
interval, are associated with high inci-
dences of minor, irritating, uncomfort-
able vasoactive reactions and have been 
proscribed.5 Chandler et al. reported on 
249 patients who received 335 iron infu-
sions of iron sucrose at doses of 200–500 
mg, all administered over 2 hours.5 The 
authors concluded that adverse events 
with the 400 and 500 mg doses were too 
high to allow recommendation of rou-
tine use of these dosage regimens over 
2 hours. The description of 5%–12% 
of patients who experienced infusion-
related side eﬀects during the study3,4 
represents a ﬁve- to tenfold increase in 
such reactions compared with those seen 
with low-molecular weight iron dextran 
or lower doses of iron sucrose.
Numerous publications now document 
that anaphylaxis, the serious adverse 
event associated with iron dextran, is 
largely due to the two high-molecular 
weight products, Imferon, which is no 
longer available, and Dexferrum, which 
is not recommended.7–15 Characteristics 
of the four available iron preparations 
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are shown in Table 1. Arthralgias and 
myalgias (chest and back tightness) after 
a test dose without tachycardia, tachyp-
nea, hypotension, wheezing, stridor, or 
angioedema occur infrequently. This 
reaction abates within minutes without 
treatment and does not recur with rechal-
lenge.7 These minor and self-limiting 
reactions to low-molecular weight iron 
dextran are sometimes treated with intra-
venous antihistamines or epinephrine, 
which themselves can cause vasoactive 
reactions incorrectly attributed to the 
iron product. Total-dose infusions of 
up to 1,500 mg of low-molecular weight 
iron dextran have been administered to 
dialysis patients without toxicity.16 In the 
ﬁrst study to show the beneﬁt of intrave-
nous iron in synergizing with erythropoi-
etin in cancer chemotherapy patients,17 
81 of 157 patients received iron dextran. 
Seventy-nine patients received low-
molecular weight iron dextran, and two 
received high-molecular weight iron 
dextran. None of the 79 patients who 
received low-molecular weight iron dex-
tran experienced a serious acute event. 
One of the two patients receiving high-
molecular weight iron dextran experi-
enced anaphylactic shock. Months later, 
low-molecular weight iron dextran was 
given to this patient uneventfully. Low-
molecular weight iron dextran, iron 
sucrose, and ferric gluconate (Ferrlecit; 
Watson, USA) can be given without sig-
niﬁcant risk with an incidence of serious 
adverse events of less than 1 in 200,000.9 
The severe anaphylactoid reaction 
described3 was almost certainly caused 
by high-molecular weight iron dextran.
Low-molecular weight iron dex-
tran has been administered without 
anaphylaxis as an intravenous push of up 
to 200 mg over 2 minutes or as a total-
dose infusion of doses up to 3,000 mg 
over 4 hours.6 Nonetheless, a test dose is 
still recommended, although the value 
of the test dose has never been validated 
in any study. In an economic analysis of 
the total-dose infusion of low-molecu-
lar weight iron dextran, this method 
of intravenous iron administration has 
been estimated to save nearly a quarter 
of a billion dollars in the 225,000 dialysis 
patients in the United States.16 In the US, 
we frequently coadminister 125 mg of 
intravenous methylprednisolone before 
and after the infusion, which alleviates 
the self-limited arthralgias and myalgias 
infrequently observed with larger doses 
of low-molecular weight iron dextran.18 
However, in Europe, premedication is 
not customary.19 In our practice, we have 
recently treated 34 patients with total-
dose infusions of low-molecular weight 
iron dextran with doses ranging from 
1,000 to 2,250 mg over 90 minutes with 
no adverse events.
Iron sucrose, ferric gluconate, and 
low-molecular weight iron dextran can 
be given without signiﬁcant risk of ana-
phylaxis, but only the last agent can be 
administered as a total-dose infusion. In 
our practices, we have given over 80,000 
doses (one dose equals 100 mg) of low-
molecular weight iron dextran without a 
single event requiring treatment or cessa-
tion of therapy. Infusion-related events are 
seen in less than 1 in 200 patients. There 
are now three published comparison tri-
als19–21 of low-molecular weight iron dex-
tran and iron sucrose, which show equal 
eﬃcacy and toxicity with considerable 
cost savings and increased convenience 
with low-molecular weight iron dextran.
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Figure 1 | Change in least-square mean urine total protein/creatinine ratio. Iron sucrose is 
represented by the solid line, and ferric gluconate is represented by the dashed line. Asterisks 
denote assessment points where the difference between the two treatments is statistically 
significant (P < 0.05). Significantly greater total protein was excreted in the urine with iron sucrose 
as early as 15 minutes post-infusion. Overall, iron sucrose resulted in greater excretion of protein in 
the urine than ferric gluconate (P < 0.001). Pr/Cr, protein/creatinine. (Reprinted from ref. 27.)
Table 1 | Currently available intravenous iron preparations 
 
Low-molecular  
weight iron dextran 
Iron saccharate Ferric gluconate 
High-molecular  
weight iron  
dextran 
Test dose required 
Vial volume 
mg iron per ml 
Black-box warning 
Total-dose infusion 
Premedication 
Preservative 
Molecular weight measured by manufacturer 
Yes
2 ml
50 mg/ml
Yes
Yes
TDI only
None
165,000 Da
No
5 ml
20 mg/ml
No
No
No
None
34,000–60,000 Da
No
5 ml
12.5 mg/ml
No
No
No
Benzyl alcohol
289,000–440,000 Da
Yes
1–2 ml
50 mg/ml
Yes
Yes
TDI only
None
265,000 Da
 
TDI, total-dose infusion. 
530   Kidney International (2008) 73 
commentar y
For patients with stages 3 and 4 chronic 
kidney disease, there are three published 
studies that suggest that iron dextran may 
have less nephrotoxicity than either iron 
sucrose or ferric gluconate.22–24 Zager et 
al.22 showed decreased recovery of kidney 
cells in rats receiving iron sucrose>ferric 
gluconate>>iron dextran. That group 
has also shown that iron sucrose exac-
erbated experimental sepsis,25 and in 
separate experiments iron sucrose>ferric 
gluconate>>iron dextran enhanced tumor 
necrosis factor-α production in animals 
given endotoxin.26
Studies in humans also suggest that low-
molecular weight iron dextran may be less 
toxic to the renal tubule. Pai et al. showed 
increased non-transferrin-bound (free) 
iron and markers of oxidative stress after a 
single dose of either iron sucrose or ferric 
gluconate compared with iron dextran.23 
Agarwal et al. showed stimulation of 
proteinuria and lipid peroxidation with 
iron sucrose in chronic kidney disease 
patients.24 Consistent with the animal 
toxicity data,22 Agarwal et al.27 recently 
published a comparative crossover study 
in chronic kidney disease patients who 
received a single dose of iron sucrose or 
ferric gluconate given as 100 mg over 
10 minutes. They found that only iron 
sucrose induced transient proteinuria 
and albuminuria (Figure 1). Although 
the clinical relevance of such transient 
eﬀects of renal tubular protein excretion 
is uncertain, these studies call into ques-
tion the wisdom of an even higher-dose 
infusion of iron sucrose to chronic kidney 
disease patients and the decision to aban-
don low-molecular weight iron dextran as 
ﬁrst-line therapy in patients with anemias 
of renal disease.
Finally, in the Jehovah’s Witnesses, who 
refuse all human blood products, per-
manent venous access is not routinely 
available as it is in oncology patients 
with indwelling catheters and dialy-
sis patients with arteriovenous shunts. 
Therefore, a single total-dose infusion 
of low-molecular weight iron dextran 
over 2 hours provides considerable 
improvements in cost and conven-
ience to a unique population with few 
other options.
We should consider the use of total-
dose infusion of low-molecular weight 
iron dextran in lieu of  high-dose 
infusions of iron sucrose, which are asso-
ciated with a high (12%) adverse-event 
rate and are more expensive. In oncology 
or dialysis patients requiring weekly or 
more frequent visits, short infusions of 
low-molecular weight iron dextran, iron 
sucrose, or ferric gluconate can be given 
without risk. If larger doses of intrave-
nous iron are to be given, the preferred 
method is a total-dose infusion of low-
molecular weight iron dextran with doses 
up to 3,000 mg administered in a single 
setting without increased toxicity. This 
method of administration is particularly 
useful in patients on home peritoneal 
dialysis as well as with other conditions 
such as iron deﬁciency due to pregnancy, 
menometrorrhagia, surgical blood loss, 
gastric bypass surgery, hereditary hem-
orrhagic telangiectasia (Osler-Weber-
Rendu), inﬂammatory bowel disease, and 
malabsorption syndromes and in those 
with uncomplicated iron deﬁciency who 
are noncompliant with or intolerant of 
oral iron.7
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